Investigating the use of Balchaturbhadra Churna for treating Allergic Bronchitis in childre
Phase 2
- Conditions
- Health Condition 1: J209- Acute bronchitis, unspecified
- Registration Number
- CTRI/2024/04/065244
- Lead Sponsor
- Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University PGIA Jodhpur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Individual between age group of 3 to 10 years of both sexes.
2. All the case of either sex, cast, and religious shall be included in the study.
3. Children diagnosed as Kasa as per contemporary medical sciences as per clinical features mentioned in Ayurvedic te
Exclusion Criteria
1. Children below 3 and above 10 years of age.
2. Patients having other acute and chronic upper and lower respiratory tract disease such as Pulmonary tuberculosis, Chronic lung disease, Bronchiectasis, Bronchogenic Carcinoma, Pneumonia, Bronchiolitis etc.
3. Patients having cardiac disease will be excluded from the study. 4. Patients having endocrinal disorders, protein energy malnutrition (PEM) disorder, and inborn error of metabolism
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The improvement in the patient primarily will be assessed mainly based on certain symptoms of the disease- Hrauit Shoola, Urha shoola (pain in chest region), Parshwa shoola(pain in flanks), Shira shoola(headache), Swara bheda (hoarseness in voice), Shushka urha kantha (dryness in mouth, throat), Hrista loma (horripilation), Daurbalya (weakness), Sukshka Kasa (dry cough), will be assessed before treatment and after treatment on subsequent 7th day, 15th day, 30th day.Timepoint: 7th, 15th, 30th day
- Secondary Outcome Measures
Name Time Method To investigate the impact of Balchaturbhadra churna on the frequency and severity of recurrent kasa episodes in children, focusing on their potential to provide relief and prevent relapsesTimepoint: 30 days